AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MAYNE PHARMA GROUP LTD

2.860

-0.060-2.05%

Volume:29.53K

Turnover:84.92K

Market Cap:234.21M

PE:13.78

High:2.960

Open:2.890

Low:2.850

Close:2.920

52wk High:6.500

52wk Low:2.040

Shares:81.89M

Float Shares:67.00M

Volume Ratio:3.29

T/O Rate:0.04%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.208

EPS(LYR):0.208

ROE:8.20%

ROA:-1.73%

PB:0.60

PE(LYR):13.78

Loading ...

Overview Company News Filings

3 Australian Biotech Stocks With Up To 77% Fair Value Upside

Simply Wall St.

Mayne Pharma Group Settles Patent Litigation With Sun Pharmaceutical Industries

MT Newswires Live

Mayne Pharma Group - Settlement Does not Include Financial Payment or Upfront Monetary Consideration

THOMSON REUTERS

Mayne Pharma Group - Generic Imvexxy Agreed Market Entry Date Set for 21 October 2032

THOMSON REUTERS

Mayne Pharma to Pay $650,000 to Settle US Generic Drug Claims

MT Newswires Live

Mayne Pharma Group - Settlement Made Without Admission of Liability or Wrongdoing by Mayne Pharma

THOMSON REUTERS

Mayne Pharma Group - Announces Agreement to Resolve Civil Complaint from 49 US States

THOMSON REUTERS

Inhibitor Therapeutics Held Annual Shareholder Meeting, Elected Directors

Australian Shares Fall; White Cliff Says Hancock Prospecting to Take 13.5% Stake With Nearly AU$9 Million Investment

MT Newswires Live

Mayne Pharma Signs Five-Year Exclusive Deal With Italfarmaco

MT Newswires Live

Mayne Pharma Group Ltd-Myx Signs Licence Agreement for Blissel in Australia

THOMSON REUTERS

Mayne Pharma Group - Signs Exclusive Five-Year Licence Agreement with Italfarmaco S.a for Blissel in Australia

THOMSON REUTERS

Inhibitor Therapeutics Announces Annual Shareholder Meeting

Are Mayne Pharma Group (ASX:MYX) Shares Undervalued As Earnings Contract?

Simply Wall St.

Inhibitor Therapeutics Announces Annual Shareholder Meeting

Mayne Pharma Group Ltd-Non-Executive Director Appointment

THOMSON REUTERS

3 ASX Penny Stocks With Market Caps Under A$2B

Simply Wall St.

Australia's Mayne Pharma Falls on Lower Unaudited Revenue and Earnings

Mayne Pharma FY Adjusted Ebitda AUD 31.7 Million

THOMSON REUTERS

Mayne Pharma FY Gross Margin 65%

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/MYX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MYX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","market":"AU","secType":"STK","nameCN":"MAYNE PHARMA GROUP LTD","latestPrice":2.86,"timestamp":1790813957439,"preClose":2.92,"halted":0,"volume":29526,"delay":0,"changeRate":-0.02054794520547947,"nameEN":"MAYNE PHARMA GROUP LTD","floatShares":66997185,"shares":81890887,"eps":0.207588,"marketStatus":"Trading","change":-0.06,"latestTime":"10-01 10:22:11 AEST","open":2.89,"high":2.96,"low":2.85,"amount":84920,"amplitude":0.037671,"askPrice":2.86,"askSize":788,"bidPrice":2.85,"bidSize":129,"shortable":3,"etf":0,"ttmEps":0.207588,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1790834400000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":2.92,"openAndCloseTimeList":[[1790812800000,1790834400000]],"volumeRatio":3.290083,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MYX.AU","preClose":2.83,"auctionPrice":2.92,"auctionVolume":20227,"auction":3,"marketStatus":"盘后竞价","timestamp":1790748600406}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","floatShares":66997185,"roa":"-1.73%","roe":"8.20%","lyrEps":0.207588,"volumeRatio":3.290083,"shares":81890887,"dividePrice":0,"high":2.96,"amplitude":0.037671,"preClose":2.92,"low":2.85,"week52Low":2.04,"pbRate":"0.60","psRate":"0.61","week52High":6.5,"institutionHeld":0,"latestPrice":2.86,"committee":-0.718648,"eps":0.207588,"divideRate":0,"volume":29526,"delay":0,"ttmEps":0.207588,"open":2.89,"prevYearClose":3.11,"prevWeekClose":2.81,"prevMonthClose":2.92,"prevQuarterClose":2.92,"fiveDayClose":2.95,"twentyDayClose":3.11,"sixtyDayClose":2.84,"dividendPayoutRate":0.04569711225089115,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0.014818181818181815},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MYX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787788800000,"name":null,"time":"","dateTimestamp":1787752800000,"actualEps":null},{"date":"2026-02-22","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771714800000,"name":null,"time":"","dateTimestamp":1771678800000,"actualEps":null},{"date":"2025-08-29","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756425600000,"name":null,"time":"","dateTimestamp":1756389600000,"actualEps":null},{"date":"2025-02-26","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null},{"date":"2024-08-23","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724371200000,"name":null,"time":"","dateTimestamp":1724335200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MYX.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2023-01-18","recordDate":"2023-01-19","paymentDate":"2023-01-27","value":0.038,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MYX.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672738443","title":"3 Australian Biotech Stocks With Up To 77% Fair Value Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2672738443","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672738443?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:20","pubTimestamp":1790763656,"startTime":"0","endTime":"0","summary":"Australia’s inflation rate sitting at 4% and interest rates at a 15 year high of 4.6% are squeezing many growth stories. Yet that pressure also pushes investors toward companies with solid balance sheets and clear funding runways. That matters for Australian biotechnology stocks, where capital access can make or break a breakthrough. This article highlights three listed biotech opportunities screened for financial resilience and reasonable value.\nThe three biotech stocks covered below are a...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-vls/vita-life-sciences-shares/news/3-australian-biotech-stocks-with-up-to-77-fair-value-upside","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-vls/vita-life-sciences-shares/news/3-australian-biotech-stocks-with-up-to-77-fair-value-upside","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["OZF.AU","ZYAU.AU","IMLC.AU","BK7096","GIVE.AU","BK4588","XKO.AU","VLS.AU","BBOZ.AU","MYX.AU","DACE.AU","VAP.AU","CUV.AU","E200.AU","BK4581","NVIB","XAO.AU","VAS.AU","IISV.AU","BK7508","BEAR.AU","GEAR.AU","BK7067","XJO.AU","EIGA.AU","QFN.AU","QRE.AU","IOZ.AU","XBI","IIGF.AU","BK4585","XBIX","SLF.AU","OZR.AU","STW.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671226535","title":"Mayne Pharma Group Settles Patent Litigation With Sun Pharmaceutical Industries","url":"https://stock-news.laohu8.com/highlight/detail?id=2671226535","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671226535?lang=en_us&edition=fundamental","pubTime":"2026-09-30 08:55","pubTimestamp":1790729716,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group  settled Paragraph IV patent litigation with Sun Pharmaceutical Industries concerning Imvexxy, an estradiol vaginal insert used to treat moderate to severe menopause-related dyspareunia, including disputes over patents listed for the drug in the US Food and Drug Administration's Orange Book, according to a Wednesday Australian bourse filing.Sun Pharma's generic version of the treatment may enter the US market on Oct. 21, 2032, or earlier under certain circumstances, subject to court approval, with no financial payment or upfront consideration between the parties, the filing said.The company said the settlement reinforces the validity and enforceability of its patent portfolio covering the product, with the final patent set to expire in February 2034, the filing added.The specialty pharmaceutical company's shares gained about 1% in recent Wednesday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7096","MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671522319","title":"Mayne Pharma Group - Settlement Does not Include Financial Payment or Upfront Monetary Consideration","url":"https://stock-news.laohu8.com/highlight/detail?id=2671522319","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671522319?lang=en_us&edition=fundamental","pubTime":"2026-09-30 07:49","pubTimestamp":1790725788,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nFWN45L1TF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671223194","title":"Mayne Pharma Group - Generic Imvexxy Agreed Market Entry Date Set for 21 October 2032","url":"https://stock-news.laohu8.com/highlight/detail?id=2671223194","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671223194?lang=en_us&edition=fundamental","pubTime":"2026-09-30 07:49","pubTimestamp":1790725788,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nFWN45L1TF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","MYX.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670631402","title":"Mayne Pharma to Pay $650,000 to Settle US Generic Drug Claims","url":"https://stock-news.laohu8.com/highlight/detail?id=2670631402","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670631402?lang=en_us&edition=fundamental","pubTime":"2026-09-28 08:15","pubTimestamp":1790554551,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group  has agreed to pay $650,000 to resolve civil claims brought by attorneys general from 49 US states and territories as part of a broader investigation into the generic pharmaceutical industry, according to a Monday Australian bourse filing.The settlement, which does not involve any admission of liability or wrongdoing, aims to avoid further legal expenses, management distraction, and uncertainty, per the filing.The company said the settlement requires only limited administrative measures, including maintaining its existing antitrust compliance policy and issuing annual compliance notices for two years, without imposing any restrictions on its business operations.The settlement remains subject to final court approval, the filing added.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MYX.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670747404","title":"Mayne Pharma Group - Settlement Made Without Admission of Liability or Wrongdoing by Mayne Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2670747404","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670747404?lang=en_us&edition=fundamental","pubTime":"2026-09-28 07:45","pubTimestamp":1790552739,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260927:nFWN45I00I:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670404742","title":"Mayne Pharma Group - Announces Agreement to Resolve Civil Complaint from 49 US States","url":"https://stock-news.laohu8.com/highlight/detail?id=2670404742","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670404742?lang=en_us&edition=fundamental","pubTime":"2026-09-28 07:45","pubTimestamp":1790552739,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260927:nFWN45I00I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","MYX.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668978711","title":"Inhibitor Therapeutics Held Annual Shareholder Meeting, Elected Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2668978711","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668978711?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:01","pubTimestamp":1789761667,"startTime":"0","endTime":"0","summary":"Inhibitor Therapeutics held annual shareholder meeting, elected directorsInhibitor Therapeutics held its annual stockholders meeting on Sept. 15, 2026.Stockholders selected six directors for one-year ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nNDL1klb8j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","MYX.AU","INTI","BK4139","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667611515","title":"Australian Shares Fall; White Cliff Says Hancock Prospecting to Take 13.5% Stake With Nearly AU$9 Million Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2667611515","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667611515?lang=en_us&edition=fundamental","pubTime":"2026-09-15 14:23","pubTimestamp":1789453413,"startTime":"0","endTime":"0","summary":"Australian shares closed lower on Tuesday, tracking losses on Wall Street as the prospect of a rate hike in the US loomed.The S&P/ASX 200 Index fell by 0.88%, or 77.40 points, to close at 8,672.50, re","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7095","VAP.AU","ZYAU.AU","XKO.AU","IMLC.AU","XJO.AU","WCN.AU","BEAR.AU","QRE.AU","BK7508","SLF.AU","NIC.AU","QFN.AU","BBOZ.AU","OZF.AU","EIGA.AU","IIGF.AU","IOZ.AU","DACE.AU","BK7096","IISV.AU","STW.AU","HBHC","XAO.AU","GEAR.AU","MYX.AU","OZR.AU","E200.AU","GIVE.AU","VAS.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667250694","title":"Mayne Pharma Signs Five-Year Exclusive Deal With Italfarmaco","url":"https://stock-news.laohu8.com/highlight/detail?id=2667250694","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667250694?lang=en_us&edition=fundamental","pubTime":"2026-09-15 08:32","pubTimestamp":1789432343,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group  has entered into an exclusive five-year agreement with Italfarmaco to register, market and distribute Blissel, an ultra-low-dose vaginal gel for menopause-related vaginal atrophy, in Australia, according to a Tuesday Australian bourse filing.Blissel is targeted for launch in fiscal 2028 through the company's existing women's health commercial team, expanding its menopause portfolio alongside NEXTSTELLIS, per the filing.Australia's topical vaginal estrogen market is worth around AU$27 million in 2025, growing at a 16% two-year compound annual growth rate, with the company expecting Blissel to contribute to international sales, the filing added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","MYX.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667691491","title":"Mayne Pharma Group Ltd-Myx Signs Licence Agreement for Blissel in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2667691491","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667691491?lang=en_us&edition=fundamental","pubTime":"2026-09-15 07:51","pubTimestamp":1789429863,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUE3VY8ZX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667496691","title":"Mayne Pharma Group - Signs Exclusive Five-Year Licence Agreement with Italfarmaco S.a for Blissel in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2667496691","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667496691?lang=en_us&edition=fundamental","pubTime":"2026-09-15 07:51","pubTimestamp":1789429863,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUE3VY8ZX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666952370","title":"Inhibitor Therapeutics Announces Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2666952370","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666952370?lang=en_us&edition=fundamental","pubTime":"2026-09-09 05:16","pubTimestamp":1788902169,"startTime":"0","endTime":"0","summary":"Inhibitor Therapeutics announces annual shareholder meetingInhibitor Therapeutics will hold its annual stockholders’ meeting virtually on Sept. 15, 2026.Stockholders will vote on matters set out in th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL7Sc3qt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","NDAQ","IE00BN0W2T93.GBP","IE00BQXX3D17.EUR","IE00B64PRP62.GBP","SG9999014039.USD","LU2210150020.SGD","SG9999014021.USD","IE00BN0W2V16.EUR","BK4139","INTI","BK7096","IE00BKPKM429.USD","SG9999014005.SGD","IE00BQXX3C00.GBP","LU0314104364.USD","SG9999014013.SGD","MYX.AU","IE00BQXX3F31.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","LU2095319765.USD","BK4588","IE00BN0W2W23.USD","BK4585","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663701558","title":"Are Mayne Pharma Group (ASX:MYX) Shares Undervalued As Earnings Contract?","url":"https://stock-news.laohu8.com/highlight/detail?id=2663701558","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663701558?lang=en_us&edition=fundamental","pubTime":"2026-08-29 02:38","pubTimestamp":1787942296,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group shares have slipped over the past week even after closing at A$3.01, leaving short term traders unimpressed. Yet the latest full year numbers tell a tougher story than the headline share price suggests. Revenue for FY26 came in at A$383.7m with underlying earnings before interest, tax, depreciation and amortisation of A$34.2m, both weaker than last year.\nThe real pivot is in the outlook. Consensus points to earnings decline over the next three years, even as the stock...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-myx/mayne-pharma-group-shares/news/are-mayne-pharma-group-asxmyx-shares-undervalued-as-earnings","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-myx/mayne-pharma-group-shares/news/are-mayne-pharma-group-asxmyx-shares-undervalued-as-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MYX","MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660794482","title":"Inhibitor Therapeutics Announces Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2660794482","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660794482?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:02","pubTimestamp":1786968142,"startTime":"0","endTime":"0","summary":"Inhibitor Therapeutics announces annual shareholder meetingInhibitor Therapeutics schedules a virtual annual stockholder meeting on Sept. 15, 2026, held via the internet.Items include election of six ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDLBW5kx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTI","MYX.AU","BK4139","BK7508","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657594604","title":"Mayne Pharma Group Ltd-Non-Executive Director Appointment","url":"https://stock-news.laohu8.com/highlight/detail?id=2657594604","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657594604?lang=en_us&edition=fundamental","pubTime":"2026-08-05 11:35","pubTimestamp":1785900920,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nTUE2LT2TP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7508","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656581918","title":"3 ASX Penny Stocks With Market Caps Under A$2B","url":"https://stock-news.laohu8.com/highlight/detail?id=2656581918","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656581918?lang=en_us&edition=fundamental","pubTime":"2026-08-04 10:08","pubTimestamp":1785809324,"startTime":"0","endTime":"0","summary":"Australian shares are poised for a modest gain today, buoyed by a positive surge in U.S. equities, particularly from strong tech sector performances. For those looking beyond the major players, penny stocks—often smaller or newer companies—remain an intriguing area of investment despite being considered somewhat outdated as a term. In this article, we explore three penny stocks that combine robust financials with potential for significant growth, offering investors the chance to uncover...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/7131000-choice2-main-header/1585186813996","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/7131000-choice2-main-header/1585186813996"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/diversified-financials/asx-rpl/regal-partners-shares/news/3-asx-penny-stocks-with-market-caps-under-a2b-5","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/diversified-financials/asx-rpl/regal-partners-shares/news/3-asx-penny-stocks-with-market-caps-under-a2b-5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RPL.AU","MYX.AU","BK7096","SSM.AU","BK7062","BK7055","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655335608","title":"Australia's Mayne Pharma Falls on Lower Unaudited Revenue and Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2655335608","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655335608?lang=en_us&edition=fundamental","pubTime":"2026-07-31 10:56","pubTimestamp":1785466577,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Mayne Pharma falls on lower unaudited revenue and earnings** Shares of Australia's Mayne Pharma GroupMYX.AXfall as much as 7.1% to A$2.415, marking their biggest intraday pct loss since March 19** Shares hit their lowest level since June 26** Specialty pharmaceutical copostsunaudited 4Q FY26 underlying EBITDA of A$4.6 million , down 76% from A$19.3 million last year** Posts unaudited 4Q FY26 revenue of A$86.5 million, down 22% from A$110.7 million in 4Q 2025** Co expects FY26 revenue to be A$383.7 million and underlying EBITDA to be A$31.7 million, down 6% and 33% on pcp, respectively** Nearly 259,300 shares change hands, about 1.3x the 30-day average** Stock down 19.3% YTD, including session's moves","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL4N43X09H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","MYX.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655647382","title":"Mayne Pharma FY Adjusted Ebitda AUD 31.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2655647382","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655647382?lang=en_us&edition=fundamental","pubTime":"2026-07-31 07:29","pubTimestamp":1785454171,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nPLX3VN256:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MYX.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655382628","title":"Mayne Pharma FY Gross Margin 65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655382628","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655382628?lang=en_us&edition=fundamental","pubTime":"2026-07-31 07:29","pubTimestamp":1785454171,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nPLX3VN256:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":54,"code":"91000000","status":"200"}]}}